Introduction
Systemic lupus erythematosus (SLE or lupus) is an autoimmune disease of unknown cause that affects multiple organs [1] . The pathologic hallmarks of SLE are dysregulated immune responses to autoantigens, with autoantibody production and subsequent inflammatory tissue injury. In the pathogenesis of lupus, innate immune cells such as dendritic cells as well as adaptive immune cells including B and T cells are involved. Patients with SLE have increased production of cytokines such as IL-10 and B-lymphocyte stimulator (BLys; also known as BAFF or B-cell activation factor of the tumor necrosis family) [2] . These cytokines could contribute to aberrant B-cell immunity by promoting B-cell maturation, survival and differentiation into plasma cells [2] . Immune complexes containing dsDNA or ssRNA (molecules in the target antigens of lupus) can activate autoreactive B cells and induce the production of IFN-a from innate immune cells such as plasmacytoid dendritic cells via the activation of Toll-like receptors (TLRs) [3] . CD4 þ T cells with the capacity to help B cells are a critical component of lupus pathogenesis. Studies indicate that pathogenic autoantibody production by autoreactive B cells in murine and human lupus is promoted by CD4 þ T-cell help in a cognate and contactdependent manner, resulting in an immune-complex mediated end-organ disease [1] . Over the past decade, our knowledge of T-cell biology has substantially increased through the discovery of new T-cell subsets including T helper (Th)17 cells [4] . Emerging data now provide new insights on the role of T-cell immunity in lupus pathogenesis. In this study, we will review the biology of Th17 cells and update the potential role of these cells in the pathogenesis of SLE.
Purpose of review
The discovery of T helper (Th)17 cells that produce the proinflammatory cytokine IL-17 has substantially advanced our understanding of T-cell biology and autoimmunity. We will review recent findings on effector T cells, in particular Th17 cells, in lupus.
Recent findings
Studies reported increased IL-17 levels in the circulation and tissues in human and murine lupus. Patients with systemic lupus erythematosus (SLE or lupus) had an increased frequency of Th17 cells in peripheral blood which correlated with disease activity. However, the frequency of IFN-g-producing Th1 cells did not change in the same patients, suggesting a selective dysregulation of Th17 cells in SLE. In addition, patients with SLE had an increased frequency of IL-17-producing CD3 þ CD4 À CD8 À (double negative) T cells in the peripheral blood and kidneys. Similar findings were noticed in lupus-prone MRL/MP-lpr/lpr (MRL/lpr) mice. A recent study demonstrated that IL-17 could promote B-cell survival and differentiation into antibody-producing cells. This raises the possibility that IL-17 is implicated in the pathogenesis of SLE by promoting humoral immunity against self-antigen. Summary Emerging data show a body of evidence that IL-17 and Th17 cells may play a role in the pathogenesis of SLE. Further studies are warranted to dissect the mechanism for increased IL-17 production and the therapeutic implication of targeting this cytokine in SLE. lymphoid tissues, naïve CD4 þ T cells become activated and proliferate with differentiation into effector T helper cells. The latter cells are critically involved in controlling the source of the antigen, including pathogens in infections and self-tissues in autoimmunity, via the induction of B-cell differentiation and macrophage activation or through cytokine production and co-stimulation.
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Effector T helper cells are not a single population and can be categorized into Th1, Th2 and Th17 cells with unique functions based on the cytokines they dominantly produce, for example, IFN-g, IL-4 and IL-17 for Th1, Th2 and Th17 cells, respectively [5, 6] . The concept of Th1 and Th2 cells was developed by Robert Coffman and Tim Mosmann more than 20 years ago. Th1 cells promote cell-mediated immune responses via the secretion of IFN-g with the capacity to activate macrophages. In fact, Th1 cells are essential for controlling intracellular microorganisms. In contrast, Th2 cells produce IL-4, IL-5 and IL-13 but not IFN-g. Cytokines from Th2 cells are involved in controlling parasites and allergens through the activation of eosinophils and the induction of IgE. Although the Th1/Th2 dichotomy has provided reasonable explanations for how distinct subsets of T helper cells are involved in controlling pathogens and developing some immune-mediated diseases such as allergies, it still has limitations in interpreting the results of various immune phenomena in infections and autoimmunity. For instance, IFN-g blocking or a genetic deficiency of IFN-g made the disease worse in mice with experimental allergic encephalitis (animal model of multiple sclerosis) which was thought to be a Th1 cell-mediated disease [4] . Indeed, this led to the discovery of a new subset of T helper cells called Th17 cells that produce the proinflammatory cytokine IL-17 (reviewed in [4-6]).
Differentiation of T helper cell subsets
The proper activation and differentiation of naïve CD4 þ T cells into effector T helper cells require multiple signals through T-cell receptor (TCR), co-stimulatory molecules and cytokines (reviewed in [5, 6] ). In addition to presenting antigen to TCR, antigen-presenting cells like dendritic cells provide the co-stimulation and cytokines for T-cell activation and differentiation. Cytokine milieu is a critical factor in determining the fate of effector T helper cells in humans and mice [5-7]. IL-12 and IFN-g promote the development of Th1 cells, whereas IL-4 enhances the differentiation of Th2 cells. For Th17 cells, multiple cytokines are involved in promoting Th17 cell development. These cytokines include IL-1b, IL-6, IL-21, IL-23 and TGF-b. Each of these cytokines appears to have a different role in optimally regulating the Th17 cell differentiation. IL-1b, IL-6 and TGF-b participate in initially differentiating Th17 cells from naive CD4 þ T cells [8] [9] [10] [11] . IL-23 is likely involved in expanding the committed Th17 cells in that naive CD4 þ T cells do not express the receptor for IL-23 [11, 12] . In contrast, IL-21 that can be self-secreted by Th17 cells stabilizes and auto-amplifies Th17 cells [11, 13] .
The cytokines involved in the T helper cell differentiation work closely with transcription factors including T box transcription factor T-bet, GATA binding protein 3 (GATA3) and retinoid orphan receptor (ROR)gt (reviewed in [6, 14] ). These transcription factors serve as the master regulators in the development of each T helper cell subset. T-bet is essential for Th1 cell differentiation, whereas GATA3 and RORgt are critical for Th2 and Th17 cell differentiation, respectively [6, 14] . The master transcription factors are tightly linked to the signaling transducer and activator of transcription (STAT) proteins that are activated by cytokines. IFN-g and IL-12 induce activation (phosphorylation) of STAT1 and STAT4, respectively, leading to the development of Th1 cells by increasing the expression of T-bet [6, 14] . IL-4 enhances GATA3 expression via activating STAT6, whereas IL-6 induces activation of STAT3, which results in increased expression of RORgt [11, 14] . The cytokines and master transcription factors involved in T helper cell differentiation appear to have reciprocal relationships [6] . T-bet can suppress GATA3 expression and RORgt [15, 16] . IFN-g and IL-4 can suppress Th17 cell differentiation [17] . In addition to RORgt, the transcription factors RORa, interferon regulatory factor (IRF)-4 and runt-related transcription factor (Runx)1 can increase Th17 cell differentiation through working in cooperation with RORgt [14] . Taken together, the differentiation of T helper cell subsets including Th17 cells is critically regulated by a complicated network of transcriptional factors in association with cytokine milieu. 
Inflammatory molecules induced by IL-17
Key points
Th17 cells produce IL-17 that can induce the production of inflammatory molecules and promote humoral immunity. Th17 cells and IL-17 may play a role in the pathogenesis of SLE in that patients with SLE have increased levels of IL-17 and expansion of IL-17producing T cells in the circulation and target organs like the kidneys. Further studies are required to determine the mechanisms for increased Th17 cell response and therapeutic benefits of blocking IL-17 in SLE.
IL-17 family cytokines [4-6]. IL-17 and IL-17F form homodimers or heterodimers [18] . IL-17 and IL-17F bind the heterodimers of IL-17 receptor A and C subunits [18] . Although IL-17 and IL-17F can drive inflammation and autoimmunity, their functions and potencies may not be equal [19] . IL-17 can induce the production of chemokines and cytokines from multiple cells including epithelial cells and fibroblasts (reviewed in [20, 21] ). IL-17 can promote the proliferation, maturation, and recruitment of neutrophils through inducing granulocyte colony-stimulating factor, granulocyte-macrophage colony stimulating factor, CXCL1, CXCL2 (MIP2a) and IL-8 (CXCL8) [20, 21] . IL-17 can also stimulate the production of the chemokines CCL2 (MCP1), CCL3 (MIP-1a), CCL7 (MCP3) and CCL20 (MIP-3a) that can recruit inflammatory cells including macrophages and lymphocytes [20, 21] . The proinflammatory cytokines IL-6 and TNF-a can be induced by IL-17 [20, 21] . IL-17 can cause tissue damage by up-regulating matrix metalloproteinases (MMPs) [20, 21] . These findings indicate that IL-17 is a potent proinflammatory cytokine with the capacity to induce the production of inflammatory and tissue-damaging molecules. Of interest, increased levels of IL-17 have been found in various immune-mediated inflammatory diseases including SLE, multiple sclerosis (MS) and psoriasis, suggesting the potential role for IL-17 in autoimmunity [21] .
Cell surface molecules associated with human Th17 cells
Human Th17 cells have unique cell surface molecules. Human Th17 cells express high levels of the chemokine receptors CCR4 and CCR6 as well as CD161, a natural killer (NK) cell-associated molecule in humans [22, 23] . Also, an increased expression of IL-1 receptor I (IL-1RI) on human Th17 cells has been reported [24 ] . Human memory CD4 þ T cells with the expression of CCR4 and CCR6 selectively produced IL-17 and expressed the transcription factor RORC (human ortholog of RORgt) [23] . CCR6 binds to CCL20 produced by Th17 cells [25] . This suggests that Th17 cells could further increase Th17 cell response via producing this chemokine. Human CD161 þ memory CD4 þ T cells had increased production of IL-17 compared with CD161-memory CD4 þ T cells, although it is unknown whether this molecule has any physiologic function in inducing Th17 cell response [23] . Of interest, human memory CD4 þ T cells with the expression of IL-1RI produced increased levels of IL-17 in response to TCR triggering and IL-1b compared with memory CD4 þ T cells without the expression of IL-1RI [24 ] . Similarly, human naïve CD4 þ T cells with the expression of IL-1RI produced IL-17 in response to a combination of IL-1b and TCR triggering, whereas the same cells without the expression of IL-1RI could not produce this cytokine. This is an intriguing observation since previous studies reported the requirement of multiple cytokines including TGF-b for the induction of IL-17 from human and mouse naive CD4 þ T cells [26] . Although these cell surface molecules are useful in identifying Th17 cells, none of them could identify a pure population of Th17 cells.
IL-17 and Th17 cells in lupus
Although CD4 þ T cells appear to be essential in the development of lupus in mice and humans, it is still unresolved which type of T helper cell plays a dominant role. Before the era of Th17 cells, the overproduction of Th1 and Th2 including IFN-g and IL-4 was reported in patients with SLE [27] [28] [29] [30] . However, recent data from human and murine studies clearly suggest the role of IL-17 and Th17 cells in lupus pathogenesis. Patients with SLE, including those with new-onset SLE, had increased plasma or serum levels of IL-17 [27, [31] [32] [33] [34] [35] [36] . In some studies, levels of this cytokine in the circulation correlated with disease activity [31, 34] . Also, such cytokine levels were even higher in lupus patients with nephritis than in those without nephritis [36] . Different types of immune cells can produce IL-17. These cells are CD4 þ T cells, CD8 þ T cells and gd-T cells as well as CD3 þ CD4 À CD8 À (double negative) T cells and NK cells [37] [38] [39] [40] . Thus, it is possible that increased IL-17 levels in the blood of patients with SLE could be secondary to enhanced IL-17 production from different types of immune cells. In fact, several independent studies reported that patients with SLE had an increased frequency of IL-17-producing CD4 þ T cells in peripheral blood which correlated with disease activity [36,41 ,42] . Also, the frequency of CD4 þ T cells that expressed the Th17-associated chemokine receptors CCR4 and CCR6 was higher in lupus patients compared with healthy controls [41 ] . Furthermore, the frequency of CCR4 þ CCR6 þ CD4 þ T cells correlated with disease activity [41 ] . In addition to CD4 þ T cells, lupus patients had expansion of double negative T cells and CD3 þ CD8 À T cells that produced high amounts of IL-17 compared with healthy controls [40, 43] . In consistence with human studies, increased expression of IL-17 was found in double negative T cells from lupus-prone MRL/MP-lpr/lpr (MRL/lpr) mice [44] . Taken together, patients with SLE have increased IL-17 production from different Tcell subsets including CD4 þ and double negative T cells.
It is still unknown why lupus patients have an increased frequency of IL-17-producing T cells. This could be secondary to enhanced T helper function in general. In a study [43] in which lupus patients were found to have an increased frequency of CD3 þ CD8 À IL-17 þ T cells in blood, the patients also had increased interferon gamma (IFNG) gene expression in peripheral blood mononuclear cells (PBMCs) and higher serum levels of the same cytokine compared with healthy controls. However, it was not clear whether this finding was secondary to increased IFN-g production from CD4 þ T cells and/or other immune cells in that IFN-g are produced by different types of immune cells. We recently measured the frequency of Th1 and Th17 cells in the peripheral blood of lupus patients and healthy controls. In this study [41 ] , lupus patients had an increased frequency of Th17 cells but not Th1 cells compared with healthy controls. Of interest, the frequency of IL-17-producing Th17 cells directly correlated with the frequency of IFN-g-producing Th1 cells in healthy controls. However, a similar correlation was not found in lupus patients. We also analyzed the ratio of CD4 þ T cells producing IL-17 to the same cells producing IFN-g since patients with SLE could have an increased frequency of both cell subsets without an alteration in the Th17/Th1 ratio [41 ] . Indeed, the ratio of Th17 to Th1 cells was higher in patients with SLE than in healthy controls. These findings indicate that an aberrant CD4 þ T-cell response occurs in lupus, resulting in a propensity toward an increased frequency of Th17 cells [41 ] . The cytokine environment is essential for Th17 cell differentiation. Thus, it is possible that the increased Th17 cell response in lupus is driven by enhanced Th17 cell-polarizing cytokines such IL-23.
Recent studies reported hyperproduction of IL-23 and expansion of IL-23 receptor-positive CD4 þ T cells in the peripheral blood of lupus patients [31, 45 ] . In lupusprone MRL/lpr mice, increased IL-23 receptor expression was found in lymph node T cells [44] . Furthermore, lymph node cells from these mice treated with IL-23 induced nephritis upon the transfer to nonautoimmune lymphocyte-deficient Rag-1 mice [44] .
Although patients with SLE have increased IL-17 production, the role for this cytokine in lupus pathogenesis is yet to be defined. As discussed above, IL-17 can induce the production of an array of inflammatory molecules (e.g. cytokines, chemokines and MMP) from immune and nonimmune cells, leading to the recruitment and activation of inflammatory cells with tissue damage. Studies with murine lupus models reported the presence of IL-17-producing T cells including double negative T cells and CD4 þ T cells in the kidneys [43, 44, 46 ] . The deficiency of the receptor for IL-23 that promoted Th17 cell differentiation prevented the development of nephritis in lupus mice [46 ,47] . Similarly, lupus patients had increased expression of IL-17 and double negative T cells in the kidneys [40, 48] . In the urine sediments from lupus patients, increased expression of the IL17 gene was found [49] . These findings suggest that IL-17 could be responsible for inflammatory tissue damage in lupus nephritis. IL-17 can promote humoral immunity that plays a major role in lupus pathogenesis. IL-17 alone or in combination with BAFF increased the survival and proliferation of human B cells as well as the differentiation of B cells into antibody-producing cells [32] . In autoimmune BXD mice, blocking IL-17 signaling reduced the development of germinal center B cells and production of autoantoantibodies including anti-dsDNA antibodies [50] . Thus, IL-17 could promote inflammation in lupus by affecting both cellular and humoral immunities.
Conclusion
Th17 cells are a recently identified subset of CD4 þ T cells. Having the capacity to produce potent proinflammatory cytokines including IL-17, this cell subset likely has an important role in autoimmunity. Studies provide a body of evidence that lupus patients have increased Th17 cell response that correlates with disease activity. In addition, IL-17 is shown to induce inflammation, tissue damage and production of autoantibodies which are essential components of lupus pathogenesis. These findings clearly raise the possible pathogenic role for IL-17 in lupus. However, additional studies are needed to find out the mechanisms for increased Th17 cell response and the therapeutic implication of targeting IL-17 in SLE.
